Sfoglia per AUTORE
LIN AB
Collezione AOU San Luigi di Orbassano
Items : 3
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. in The New England journal of medicine / N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21.
2023
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.
2021
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Novello S; F Loong HH; Lin BK; Lin AB; Sashegyi A; Soldatenkova V; Davis HM; Elamin Y; Wolf J; Park K; Drilon A; Zhou CC; Solomon BJ; Arriola E; Pérol M; Goto K; Santini FC;
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. in Investigational new drugs / Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.
2016
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M;